EP Patent

EP4162928A1 — Rifamycin for the treatment of pouchitis, with an in-situ gelling formulation

Assigned to Cosmo Technologies Ltd · Expires 2023-04-12 · 3y expired

What this patent protects

The present application relates to an in situ enema containing Rifamycin SV and its use in the treatment of pouchitis. More particularly, the present application describes an in situ gelling retentive enema containing Rifamycin SV for treating, ameliorating, reducing the severity…

USPTO Abstract

The present application relates to an in situ enema containing Rifamycin SV and its use in the treatment of pouchitis. More particularly, the present application describes an in situ gelling retentive enema containing Rifamycin SV for treating, ameliorating, reducing the severity of or slowing the progression of pouchitis.

Drugs covered by this patent

Patent Metadata

Patent number
EP4162928A1
Jurisdiction
EP
Classification
—
Expires
2023-04-12
Drug substance claim
No
Drug product claim
No
Assignee
Cosmo Technologies Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.